ArticleAnnals of the rheumatic diseases2021
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.
Article in Annals of the rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.Annals of the rheumatic diseases · 2021Guideline
- Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.Annals of the rheumatic diseases · 2022Trial
- Management of Late-Onset Rheumatoid Arthritis with Treat-to-Target Strategy.Drugs & aging · 2025Review
- Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance.Rheumatology and therapy · 2024Article
- Low-Dose Glucocorticoids in Older Patients with Rheumatoid Arthritis: What Does the Evidence Say?Drugs & aging · 2024Review
- Selective JAK-Inhibitors in Spondyloarthritis.Mediterranean journal of rheumatology · 2024Review
- Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.Annals of the rheumatic diseases · 2024Review
- Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.Scientific reports · 2023Article
- Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis.Therapeutic advances in chronic disease · 2023Review
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs.Clinical, cosmetic and investigational dermatology · 2023Review
- The infection risks of JAK inhibition.Expert review of clinical immunology · 2022Article
- Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?Mediterranean journal of rheumatology · 2022Review
- User's guide to JAK inhibitors in inflammatory bowel disease.Current research in pharmacology and drug discovery · 2022Review
- Clinical characteristics of ulcerative colitis in elderly patients.JGH open : an open access journal of gastroenterology and hepatology · 2021Review
- Article
- Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review.Rheumatology and therapy · 2021Review
- Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis.Open access rheumatology : research and reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.